.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Boehringer Ingelheim
Covington
Farmers Insurance
US Army
Fuji
Baxter
QuintilesIMS
Harvard Business School
Cantor Fitzgerald
Federal Trade Commission

Generated: September 24, 2017

DrugPatentWatch Database Preview

MOVIPREP Drug Profile

« Back to Dashboard

Which patents cover Moviprep, and when can generic versions of Moviprep launch?

Moviprep is a drug marketed by Salix Pharms and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has forty-three patent family members in nineteen countries.

The generic ingredient in MOVIPREP is ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate. There are six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate profile page.

Summary for Tradename: MOVIPREP

Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Clinical Trials: see list27
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:MOVIPREP at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Salix Pharms
MOVIPREP
ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate
FOR SOLUTION;ORAL021881-001Aug 2, 2006RXYesYes► Subscribe► SubscribeYY ► Subscribe
Salix Pharms
MOVIPREP
ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate
FOR SOLUTION;ORAL021881-001Aug 2, 2006RXYesYes► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for MOVIPREP

Drugname Dosage Strength RLD Submissiondate
polyethylene glycol 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and For Oral Solution100 g, 7.5 g, 2.691 g, 1.015 g, 5.9 g and 4.7 g per pouchMoviprep11/27/2007

International Patent Family for Tradename: MOVIPREP

Country Document Number Estimated Expiration
Hong Kong1077196► Subscribe
Canada2672427► Subscribe
World Intellectual Property Organization (WIPO)2004037292► Subscribe
Russian Federation2353412► Subscribe
Spain2285970► Subscribe
Japan5660320► Subscribe
Slovenia1567193► Subscribe
Spain2319093► Subscribe
Canada2502103► Subscribe
Russian Federation2005116023► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Farmers Insurance
Fuji
Boehringer Ingelheim
Healthtrust
US Department of Justice
Federal Trade Commission
Cerilliant
Accenture
Baxter
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot